Immunotherapy in prostate cancer: challenges and opportunities.
about
Immunobiology and immunotherapy in genitourinary malignanciesSafety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.Mangiferin functionalized radioactive gold nanoparticles (MGF-198AuNPs) in prostate tumor therapy: green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy.Technical Feasibility of Tissue Microarray (TMA) Analysis of Tumor-Associated Immune Response in Prostate Cancer.
P2860
Immunotherapy in prostate cancer: challenges and opportunities.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Immunotherapy in prostate cancer: challenges and opportunities.
@en
type
label
Immunotherapy in prostate cancer: challenges and opportunities.
@en
prefLabel
Immunotherapy in prostate cancer: challenges and opportunities.
@en
P2093
P2860
P356
P1433
P1476
Immunotherapy in prostate cancer: challenges and opportunities.
@en
P2093
Fukuko Moriya
Kyogo Itoh
Masanori Noguchi
Noriko Koga
P2860
P356
10.2217/IMT.15.101
P577
2015-12-07T00:00:00Z